Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MILESTONE: MRD-adapted AHCT Deferral in Multiple Myeloma
NCT04991103Phase 2Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Sep 2021
- Primary completion
- Jan 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of daratumumab in multiple myeloma (MM), sponsored by University of Alabama at Birmingham. Primary endpoint: Minimal Residual Disease Negativity Rate at 6 months. Started Sep 2021; status: recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04991103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04991103.